Logo image of 9VC.DE

ATAI LIFE SCIENCES NV (9VC.DE) Stock Fundamental Analysis

FRA:9VC - Deutsche Boerse Ag - NL0015000DX5 - Common Stock - Currency: EUR

1.3785  -0.08 (-5.19%)

Fundamental Rating

2

Overall 9VC gets a fundamental rating of 2 out of 10. We evaluated 9VC against 52 industry peers in the Pharmaceuticals industry. The financial health of 9VC is average, but there are quite some concerns on its profitability. 9VC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 9VC has reported negative net income.
9VC had a negative operating cash flow in the past year.
9VC had negative earnings in each of the past 5 years.
9VC had a negative operating cash flow in each of the past 5 years.
9VC.DE Yearly Net Income VS EBIT VS OCF VS FCF9VC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

9VC's Return On Assets of -65.11% is on the low side compared to the rest of the industry. 9VC is outperformed by 82.69% of its industry peers.
9VC's Return On Equity of -88.25% is on the low side compared to the rest of the industry. 9VC is outperformed by 78.85% of its industry peers.
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROIC N/A
ROA(3y)-34.71%
ROA(5y)-55.84%
ROE(3y)-39.84%
ROE(5y)-66.13%
ROIC(3y)N/A
ROIC(5y)N/A
9VC.DE Yearly ROA, ROE, ROIC9VC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 9VC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
9VC.DE Yearly Profit, Operating, Gross Margins9VC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 9VC has about the same amount of shares outstanding.
Compared to 1 year ago, 9VC has a worse debt to assets ratio.
9VC.DE Yearly Shares Outstanding9VC.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
9VC.DE Yearly Total Debt VS Total Assets9VC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

9VC has an Altman-Z score of -2.94. This is a bad value and indicates that 9VC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.94, 9VC is not doing good in the industry: 67.31% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.14 indicates that 9VC is not too dependend on debt financing.
The Debt to Equity ratio of 9VC (0.14) is better than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACC7.19%
9VC.DE Yearly LT Debt VS Equity VS FCF9VC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

9VC has a Current Ratio of 5.81. This indicates that 9VC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.81, 9VC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
9VC has a Quick Ratio of 5.81. This indicates that 9VC is financially healthy and has no problem in meeting its short term obligations.
9VC's Quick ratio of 5.81 is amongst the best of the industry. 9VC outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
9VC.DE Yearly Current Assets VS Current Liabilites9VC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

9VC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.00%.
Looking at the last year, 9VC shows a decrease in Revenue. The Revenue has decreased by -2.65% in the last year.
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164%
Revenue 1Y (TTM)-2.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.02%

3.2 Future

The Earnings Per Share is expected to grow by 54.45% on average over the next years. This is a very strong growth
Based on estimates for the next years, 9VC will show a very strong growth in Revenue. The Revenue will grow by 275.61% on average per year.
EPS Next Y-189.82%
EPS Next 2Y-48.27%
EPS Next 3Y-29.96%
EPS Next 5Y54.45%
Revenue Next Year21.83%
Revenue Next 2Y-25.88%
Revenue Next 3Y-12.96%
Revenue Next 5Y275.61%

3.3 Evolution

9VC.DE Yearly Revenue VS Estimates9VC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
9VC.DE Yearly EPS VS Estimates9VC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 9VC. In the last year negative earnings were reported.
Also next year 9VC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
9VC.DE Price Earnings VS Forward Price Earnings9VC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
9VC.DE Per share data9VC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as 9VC's earnings are expected to decrease with -29.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.27%
EPS Next 3Y-29.96%

More info and screens

0

5. Dividend

5.1 Amount

9VC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

FRA:9VC (3/7/2025, 7:00:00 PM)

1.3785

-0.08 (-5.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners27.75%
Inst Owner ChangeN/A
Ins Owners3.57%
Ins Owner ChangeN/A
Market Cap231.31M
Analysts83.33
Price Target6.8 (393.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.67%
Min EPS beat(2)-115.21%
Max EPS beat(2)-0.12%
EPS beat(4)2
Avg EPS beat(4)-19.73%
Min EPS beat(4)-115.21%
Max EPS beat(4)27.97%
EPS beat(8)5
Avg EPS beat(8)15.76%
EPS beat(12)7
Avg EPS beat(12)-2.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.22%
PT rev (3m)1.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 758.72
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.71%
ROA(5y)-55.84%
ROE(3y)-39.84%
ROE(5y)-66.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.49%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -2.94
F-Score2
WACC7.19%
ROIC/WACCN/A
Cap/Depr(3y)1014.98%
Cap/Depr(5y)708.99%
Cap/Sales(3y)212.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164%
EPS Next Y-189.82%
EPS Next 2Y-48.27%
EPS Next 3Y-29.96%
EPS Next 5Y54.45%
Revenue 1Y (TTM)-2.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.02%
Revenue Next Year21.83%
Revenue Next 2Y-25.88%
Revenue Next 3Y-12.96%
Revenue Next 5Y275.61%
EBIT growth 1Y19.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.78%
EBIT Next 3Y-7.51%
EBIT Next 5Y-5.62%
FCF growth 1Y16.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.21%
OCF growth 3YN/A
OCF growth 5YN/A